CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity

[1]  Jordan G Bryan,et al.  Genome-scale screens identify factors regulating tumor cell responses to natural killer cells , 2021, Nature Genetics.

[2]  Prahlad T. Ram,et al.  Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype , 2021, Cell reports.

[3]  Qiulian Wu,et al.  CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies. , 2020, Cancer discovery.

[4]  A. Šarić,et al.  An ESCRT-III Polymerization Sequence Drives Membrane Deformation and Fission , 2020, Cell.

[5]  Amber L. Simpson,et al.  Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers , 2020, Cell.

[6]  D. Tang,et al.  ESCRT-III-mediated membrane repair in cell death and tumor resistance , 2020, Cancer Gene Therapy.

[7]  Kathryn A. O’Donnell,et al.  eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer , 2020, Nature Cancer.

[8]  J. Rich,et al.  Glioblastoma Stem Cells: Driving Resilience through Chaos. , 2020, Trends in cancer.

[9]  Raghu Kalluri,et al.  The biology, function, and biomedical applications of exosomes , 2020, Science.

[10]  K. D. de Visser,et al.  Immune crosstalk in cancer progression and metastatic spread: a complex conversation , 2020, Nature Reviews Immunology.

[11]  J. Kirkwood,et al.  Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells , 2020, Scientific Reports.

[12]  D. Campana,et al.  NK cells for cancer immunotherapy , 2020, Nature Reviews Drug Discovery.

[13]  S. Tugues,et al.  The Interplay Between Innate Lymphoid Cells and the Tumor Microenvironment , 2019, Front. Immunol..

[14]  M. Donia,et al.  Genome-wide CRISPR-Cas9 Screening Reveals Ubiquitous T cell Cancer Targeting via the monomorphic MHC class I related protein MR1 , 2019, Nature Immunology.

[15]  C. Genova,et al.  Harnessing NK Cells for Cancer Treatment , 2019, Front. Immunol..

[16]  N. Xu,et al.  Exosomes in Head and Neck Squamous Cell Carcinoma , 2019, Front. Oncol..

[17]  Andrew R. Morton,et al.  Targeting Glioblastoma Stem Cells through Disruption of the Circadian Clock. , 2019, Cancer discovery.

[18]  Frances M. G. Pearl,et al.  Cell-derived extracellular vesicles can be used as a biomarker reservoir for glioblastoma tumor subtyping , 2019, Communications Biology.

[19]  L. Shevde,et al.  The Tumor Microenvironment Innately Modulates Cancer Progression. , 2019, Cancer research.

[20]  M. Caligiuri,et al.  Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion , 2019, Nature.

[21]  M. Heller,et al.  A Pilot Proof-Of-Principle Analysis Demonstrating Dielectrophoresis (DEP) as a Glioblastoma Biomarker Platform , 2019, Scientific Reports.

[22]  J. Settleman,et al.  Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance , 2019, bioRxiv.

[23]  Michael Boutros,et al.  CRISPR/Cas9 for cancer research and therapy. , 2019, Seminars in cancer biology.

[24]  L. Lanier,et al.  Natural Killer Cells in Cancer Immunotherapy , 2019, Annual Review of Cancer Biology.

[25]  Qiulian Wu,et al.  N 6 -methyladenine DNA Modification in Glioblastoma , 2018, Cell.

[26]  E. Alici,et al.  The Role of CXC Chemokine Receptors 1–4 on Immune Cells in the Tumor Microenvironment , 2018, Front. Immunol..

[27]  É. Vivier,et al.  Natural killer cells and other innate lymphoid cells in cancer , 2018, Nature Reviews Immunology.

[28]  X. Breakefield,et al.  Multidimensional communication in the microenvirons of glioblastoma , 2018, Nature Reviews Neurology.

[29]  M. Ferrer,et al.  High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer , 2018, Scientific Reports.

[30]  M. Ferrer,et al.  High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer , 2018, Scientific Reports.

[31]  Qinglin Liu,et al.  Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways , 2018, Oncogene.

[32]  R. Weinberg,et al.  Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.

[33]  Charles H. Yoon,et al.  Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity , 2018, Science.

[34]  J. Freeman,et al.  MicroRNA-223 Suppresses the Canonical NF-κB Pathway in Basal Keratinocytes to Dampen Neutrophilic Inflammation , 2018, Cell reports.

[35]  D. Largaespada,et al.  CRISPR/Cas9 library screening for drug target discovery , 2018, Journal of Human Genetics.

[36]  V. Budach,et al.  Heat shock protein 70 and tumor‐infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK‐ROG) , 2017, International journal of cancer.

[37]  Feng Zhang,et al.  Identification of essential genes for cancer immunotherapy , 2017, Nature.

[38]  Bo Zhang,et al.  Glioma cells enhance angiogenesis and inhibit endothelial cell apoptosis through the release of exosomes that contain long non-coding RNA CCAT2 , 2017, Oncology reports.

[39]  Theofanis Floros,et al.  Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer , 2017, Clinical Cancer Research.

[40]  Hong-Hee Kim,et al.  NF-κB signaling regulates cell-autonomous regulation of CXCL10 in breast cancer 4T1 cells , 2017, Experimental &Molecular Medicine.

[41]  S. Stylli,et al.  The emergent role of exosomes in glioma , 2017, Journal of Clinical Neuroscience.

[42]  A. Hakimi,et al.  The head and neck cancer immune landscape and its immunotherapeutic implications. , 2016, JCI insight.

[43]  G. Bernardini,et al.  Dysregulation of Chemokine/Chemokine Receptor Axes and NK Cell Tissue Localization during Diseases , 2016, Front. Immunol..

[44]  Johannes Schöneberg,et al.  Reverse-topology membrane scission by the ESCRT proteins , 2016, Nature Reviews Molecular Cell Biology.

[45]  Gabriela Alexe,et al.  Characterizing genomic alterations in cancer by complementary functional associations , 2016, Nature Biotechnology.

[46]  M. Gonzalez-Gaitan,et al.  ESCRT proteins restrict constitutive NF-κB signaling by trafficking cytokine receptors , 2016, Science Signaling.

[47]  Jun S. Liu,et al.  Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR , 2015, Genome Biology.

[48]  I. Pastan,et al.  Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1&agr;-secreting Glioblastoma , 2015, Journal of immunotherapy.

[49]  L. Mincheva-Nilsson,et al.  Prostate Tumor-Derived Exosomes Down-Regulate NKG2D Expression on Natural Killer Cells and CD8+ T Cells: Mechanism of Immune Evasion , 2014, PloS one.

[50]  B. Carter,et al.  Extracellular vesicles as a platform for ‘liquid biopsy’ in glioblastoma patients , 2014, Expert review of molecular diagnostics.

[51]  J. Zimmer,et al.  Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level , 2013, Journal of Neuroimmunology.

[52]  Xiang Gao,et al.  Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation , 2013, Journal of Translational Medicine.

[53]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[54]  J. Akers,et al.  Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies , 2013, Journal of Neuro-Oncology.

[55]  T. Whiteside.  Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). , 2013, Biochemical Society transactions.

[56]  B. Carr,et al.  Company profile: NanoSight: delivering practical solutions for biological nanotechnology. , 2012, Nanomedicine.

[57]  L. Hurton,et al.  Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells , 2012, PloS one.

[58]  Mingli Liu,et al.  The emerging role of CXCL10 in cancer (Review). , 2011, Oncology letters.

[59]  L. Mincheva-Nilsson,et al.  Thermal- and Oxidative Stress Causes Enhanced Release of NKG2D Ligand-Bearing Immunosuppressive Exosomes in Leukemia/Lymphoma T and B Cells , 2011, PloS one.

[60]  N. Friedman,et al.  Densely Interconnected Transcriptional Circuits Control Cell States in Human Hematopoiesis , 2011, Cell.

[61]  M. Belvisi,et al.  TNFα and IFNγ synergistically enhance transcriptional activation of CXCL10 in human airway smooth muscle cells via STAT-1, NF-κB, and the transcriptional coactivator CREB-binding protein. , 2010, The Journal of biological chemistry.

[62]  Roger E. McLendon,et al.  Targeting A20 Decreases Glioma Stem Cell Survival and Tumor Growth , 2010, PLoS biology.

[63]  J. Skepper,et al.  Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. , 2010, Cancer research.

[64]  Carmen Visus,et al.  Tumor-Derived Microvesicles Promote Regulatory T Cell Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8+ T Lymphocytes1 , 2009, The Journal of Immunology.

[65]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[66]  A. Cerwenka,et al.  Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. , 2008, Cancer research.

[67]  S. Emr,et al.  Ordered assembly of the ESCRT-III complex on endosomes is required to sequester cargo during MVB formation. , 2008, Developmental cell.

[68]  Jacob Piehler,et al.  Helical Structures of ESCRT-III Are Disassembled by VPS4 , 2008, Science.

[69]  M. Mason,et al.  Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression1 , 2008, The Journal of Immunology.

[70]  A. Guha,et al.  Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells , 2008, Nature Cell Biology.

[71]  Aled Clayton,et al.  Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. , 2007, Cancer research.

[72]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[73]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[74]  G. Parmiani,et al.  Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. , 2005, Gastroenterology.

[75]  C. Yee,et al.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.

[76]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[77]  박혜영.  NF-kappa B signaling regulates cell-autonomous regulation of CXCL10 in breast cancer 4T1 cells , 2017 .

[78]  Y. Samuels,et al.  The head and neck cancer cell oncogenome : a platform for the development of precision molecular therapies , 2014 .